Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q00872
UPID:
MYPC1_HUMAN
Alternative names:
C-protein, skeletal muscle slow isoform
Alternative UPACC:
Q00872; B4DKR5; B7Z8G8; B7ZL02; B7ZL09; B7ZL10; E7ESM5; E7EWS6; G3XAE8; Q15497; Q17RR7; Q569K7; Q86T48; Q86TC8; Q8N3L2
Background:
Myosin-binding protein C, slow-type, also known as C-protein, skeletal muscle slow isoform, plays a pivotal role in muscle contraction. It is a thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands, binding to both myosin and actin. This protein modulates the activity of actin-activated myosin ATPase, potentially influencing muscle contraction or serving a structural role.
Therapeutic significance:
Linked to diseases such as Arthrogryposis, distal, 1B, Lethal congenital contracture syndrome 4, and Congenital myopathy 16, Myosin-binding protein C, slow-type's genetic variants underscore its clinical importance. Understanding its role could open doors to potential therapeutic strategies, offering hope for targeted interventions in these muscular disorders.